Table 1 Summary of the twenty-three included studies
From: Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis
Study | Origin of population | Study design | Disease | Number | Stage | SNHG7 assay | Survival analysis | Metastasis analysis | Hazard ratios | Follow-up Months | |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Chen 2018 [10] | China | R | Bladder cancer | 92 | I-III/IV | qRT-PCR | OS | LNM/DM | K-M | 60 |
2 | Cheng 2019 [25] | China | R | Pancreatic cancer | 40 | I-II/III-IV | qRT-PCR | OS | LNM | K-M | 50 |
3 | Chi 2018 [49] | China | R | Neuroblastoma | 92 | I-IIA/IIB-IV | qRT-PCR | OS | LNM | K-M | 60 |
4 | Hu 2019 [35] | China | R | Colorectal cancer | 738 | NA | TCGA database | OS | NA | K-M | 14 |
5 | Jia 2020 [36] | China | R | Neuroblastoma | 45 | I-II/III-IV | qRT-PCR | OS | NA | K-M | 60 |
6 | Jiang 2020 [37] | China | R | Breast cancer | 57 | I-II/III-IV | qRT-PCR | NA | LNM | NA | NA |
7 | Li 2018 [38] | China | R | Colorectal cancer | 70 | I-II/III-IV | qRT-PCR | OS/DFS | LNM/DM | K-M | 60 |
8 | Pang 2020 [39] | China | R | Non-small cell lung cancer | 42 | I-II/III-IV | qRT-PCR | NA | LNM | NA | NA |
9 | Qi 2018 [20] | China | R | Prostate cancer | 42 | II/III-IV | qRT-PCR | OS | LNM | K-M | 60 |
10 | Shan 2018 [24] | China | R | Colorectal cancer | 48 | I-II/III-IV | qRT-PCR | OS | LNM/DM | K-M | 72 |
11 | Shen 2020 [40] | China | R | Hepatocellular carcinoma | 100 | I-II/III-IV | qRT-PCR | OS/PFS | LNM | K-M | 60 |
12 | Wang 2019 [18] | China | R | Thyroid cancer | 64 | I-II/III-IV | qRT-PCR | NA | LNM | NA | NA |
13 | China | R | Melanoma | 80 | I-II/III-IV | qRT-PCR | OS | LNM/DM | K-M | 48 | |
14 | Wu 2019 [6] | China | R | Hypopharyngeal Cancer | 73 | I-II/III-IV | qRT-PCR | OS | LNM/DM | K-M | 60 |
15 | Wu 2020 [42] | China | R | Cervical Cancer | 51 | I-II/III-IV | qRT-PCR | OS | LNM | K-M | 60 |
16 | Xia 2019 [50] | China | R | Prostate cancer | 127 | I-II/III-IV | qRT-PCR | OS | LNM/DM | HR/K-M | 60 |
17 | Xie 2020 [43] | China | R | Hepatocellular carcinoma | 80 | NA | qRT-PCR | OS | NA | K-M | 60 |
18 | Yang 2019 [44] | China | R | Hepatocellular carcinoma | 80 | NA | qRT-PCR | OS | NA | K-M | 60 |
19 | Zeng 2019 [45] | China | R | Cervical cancer | 60 | I-II/III-IV | qRT-PCR | OS | LNM | HR/K-M | 60 |
20 | Zhang 2019 [7] | China | R | Gastric cancer | 162 | I-II/III-IV | qRT-PCR | OS | LNM/DM | K-M | 96 |
21 | China | R | Colorectal cancer | 96 | I/II-III | qRT-PCR | OS | LNM | K-M | 40 | |
22 | Zhao 2020 [48] | China | R | Cervical cancer | 45 | I-II/III-IV | qRT-PCR | OS | LNM | K-M | 50 |
23 | Zhong 2018 [21] | China | R | Bladder cancer | 134 | I/II-IV | qRT-PCR | NA | LNM | NA | 36 |